Showing results (211-220 of 247) with videos related to
Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumorsKwok-K Wong, Paula M Fracasso, Ronald M Bukowski, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 9, 2008
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancerAlberto F Sobrero, Joan Maurel, Louis Fehrenbacher, et al.European Journal of Cancer (Oxford, England : 1990)|June 6, 2013
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 studyMario Campone, Thomas Bachelot, Michael Gnant, et al.The Lancet. Oncology|June 21, 2015
Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trialSara A Hurvitz, Fabrice Andre, Zefei Jiang, et al.The New England Journal of Medicine|March 9, 2022
Overall Survival with Ribociclib plus Letrozole in Advanced Breast CancerGabriel N Hortobagyi, Salomon M Stemmer, Howard A Burris, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2016
Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid TumorsSaoirse O Dolly, Andrew J Wagner, Johanna C Bendell, et al.Frontiers in Oncology|February 28, 2022
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b StudySara M Tolaney, Muralidhar Beeram, J Thaddeus Beck, et al.The Lancet. Oncology|July 19, 2012
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trialJeffrey R Infante, Leslie A Fecher, Gerald S Falchook, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2009
Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancerLecia V Sequist, Panos M Fidias, Jennifer S Temel, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2025
The Bi-steric, mTORC1-Selective Inhibitor, RMC-5552, in Advanced Solid Tumors: A Phase 1 TrialAlison M Schram, Abdul Rafeh Naqash, Eric B Haura, et al.Pageof 25